Brief: Erytech Pharma H1 Net Loss Narrows To 28.0 Million Euros

Phaxiam Therapeutics SA

21/09/2021 07:35

Sept 21 (Reuters) - ERYTECH PHARMA SA  ERY.PA :
    * PUBLISHED ON MONDAY BUSINESS UPDATE AND REPORTS FINANCIAL
RESULTS FOR THE FIRST HALF OF 2021
    * TRYBECA-1 PHASE 3 TRIAL OF ERYASPASE IN SECOND-LINE
METASTATIC
PANCREATIC CANCER FULLY ENROLLED SINCE JANUARY 2021; ON TRACK
FOR FINAL RESULTS IN Q4 2021
    * CASH AND CASH EQUIVALENTS OF € 44.5 MILLION ($54.9
MILLION) AT
THE END OF JUNE 2021
    * H1 NET LOSS EUR 28.0 MLN VS LOSS OF EUR 35.0 MLN YEAR AGO
    * H1 OPERATING LOSS EUR 29.0 MLN VS LOSS OF EUR 35.4 MLN
YEAR AGO
    * POTENTIAL BLA FILING OF ERYASPASE IN HYPERSENSITIVE ALL
(Q4
2021) 
    * DETERMINATION OF THE MAXIMUM TOLERATED DOSE IN RESPECT,
PHASE 1
IST IN 1L PAC (Q4 2021)
    * POTENTIAL BLA FILING OF ERYASPASE IN 2L PANCREATIC CANCER
(1H
2022) 
    * INITIAL (INTERIM) DATA FROM THE RANDOMIZED PHASE 2
TRYBECA-2
TRIAL OF ERYASPASE IN TNBC (1H 2022)

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNE3VJFW5
    
 Further company coverage:  ERY.PA  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))